Intellia Therapeutics

General Information
Business:

We are a leading gene editing company focused on the development of proprietary, potentially curative therapeutics utilizing a recently developed biological tool known as the CRISPR/Cas9 system. We believe that the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. We intend to leverage our leading scientific expertise, clinical development experience and intellectual property position to unlock broad therapeutic applications of CRISPR/Cas9 gene editing and develop a potential new class of therapeutic products.

Industry: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Employees: 61
Founded: 2014
Contact Information
Address 130 Brookline Street, Suite 201, Cambridge, MA 02139, US
Phone Number (857) 285-6200
Web Address http://www.intelliatx.com
View Prospectus: Intellia Therapeutics
Financial Information
Market Cap $631.8mil
Revenues $6.0 mil (last 12 months)
Net Income $-12.4 mil (last 12 months)
IPO Profile
Symbol NTLA
Exchange NASDAQ
Shares (millions): 6.0
Price range $18.00 - $18.00
Est. $ Volume $108.0 mil
Manager / Joint Managers Credit Suisse/ Jefferies/ Leerink Partners
CO-Managers Wedbush PacGrow
Expected To Trade: 5/6/2016
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change